Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iso-[131I]SGMIB-HF-22
- Development stage
- Preclinical
- Lead developer
- Fudan University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
iso-[131I]SGMIB-HF-22 is a radio-halogenated single-domain antibody (VHH or nanobody) targeting Claudin-18.2 (CLDN18.2), developed as a therapeutic radiopharmaceutical for gastrointestinal malignancies, particularly gastric and pancreatic cancers. The agent consists of the CLDN18.2-specific VHH clone HF-22 conjugated to the therapeutic radionuclide iodine-131 (131I) via the prosthetic group iso-SGMIB (iso-succinimidyl 4-guanidinomethyl-3-iodobenzoate). This specific formulation is designed to reduce renal and gastric retention, which are common limitations of VHH-based radiopharmaceuticals. In preclinical models, iso-[131I]SGMIB-HF-22 demonstrated high tumor uptake, rapid renal and gastric clearance, and significant dose-dependent tumor growth suppression without apparent toxicity.
- Other names
- 131I-labeled CLDN18.2-targeted VHH HF-22iso-131I-SGMIB-HF-22iso131I-SGMIB-HF-22iso 131I-SGMIB-HF-22
02
Targets
Claudin 18.2
Beyond the preview
Go deeper on iso-[131I]SGMIB-HF-22.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iso-[131I]SGMIB-HF-22.